Scientists have identified a previously overlooked biological mechanism that appears to help the brain determine when to stop scratching, providing new insight into how the nervous system regulates itch. The findings could eventually contribute to more targeted treatments for chronic itch associated with skin diseases.
The research, presented at the 70th Biophysical Society Annual Meeting, focused on a molecule known as TRPV4, an ion channel found in sensory nerve cells. Ion channels act as microscopic gateways that open in response to mechanical or chemical stimuli, allowing ions to move across cell membranes and transmit signals throughout the nervous system.
TRPV4 belongs to a family of ion channels involved in sensing temperature, pressure, and tissue stress. Although researchers have long suspected that TRPV4 contributes to the detection of mechanical stimulation, its role in itch—particularly chronic itch—has remained uncertain.
Mouse Experiments Revealed an Unexpected Pattern
Roberta Gualdani and colleagues at the University of Louvain in Brussels investigated TRPV4 while studying the biology of pain. To isolate its role more precisely, they engineered mice in which TRPV4 was removed only from sensory neurons rather than from every cell in the body, overcoming a limitation of earlier studies.
Using genetic techniques, calcium imaging, and behavioral analyses, the researchers mapped the distribution of TRPV4 within the nervous system. They detected the channel in touch-sensitive neurons known as Aβ low-threshold mechanoreceptors, as well as in neurons involved in itch and pain signaling, including those expressing the well-known ion channel TRPV1.
The team then induced a chronic itch condition resembling atopic dermatitis, the most common form of eczema. They compared scratching behavior between normal mice and mice lacking TRPV4 specifically in their sensory neurons.
A Signal That Appears to Tell the Brain “Enough”
The results revealed an unexpected pattern. Mice lacking neuronal TRPV4 scratched less often than normal mice, but each scratching episode lasted significantly longer. According to the researchers, this finding suggests that TRPV4 is involved in regulating scratching behavior rather than simply generating itch sensations.
The researchers propose that TRPV4 helps activate a negative feedback mechanism within mechanosensory neurons. This feedback may signal to the spinal cord and brain that scratching has provided sufficient relief.
When this signaling pathway functions normally, scratching eventually becomes satisfying and naturally stops. Without TRPV4 in sensory neurons, however, this feedback appears to weaken, causing the animals to continue scratching for longer periods even though scratching episodes occur less frequently.
Implications for Future Itch Treatments
The findings suggest that TRPV4 may serve different functions depending on where it is located. In skin cells, the channel may contribute to initiating itch signals, whereas within sensory neurons it appears to help limit scratching once it begins.
This dual role presents challenges for developing medications that broadly block TRPV4 activity. While inhibiting the channel in skin tissue might reduce itch signals, suppressing TRPV4 in sensory neurons could interfere with the nervous system’s natural mechanism for stopping scratching.
The researchers therefore suggest that future therapies may need to target TRPV4 selectively within the skin while preserving its function in sensory neurons. Such an approach could reduce itch without disrupting the body’s own feedback system.
Implications for Chronic Itch Disorders
Chronic itch affects millions of people living with conditions such as atopic dermatitis, psoriasis, chronic kidney disease, and liver disease. Persistent scratching can damage the skin, increase the risk of infection, disrupt sleep, and negatively affect mental wellbeing.
Much of the recent progress in treating chronic itch has focused on the immune system. Newer therapies target inflammatory pathways, including medications that block interleukin-4 and interleukin-13 or inhibit Janus kinases, helping reduce inflammation and itch intensity.
The new findings highlight an additional aspect of chronic itch by demonstrating how the nervous system itself may regulate scratching behavior. Researchers suggest that combining treatments targeting both immune and neural pathways could eventually provide more effective and longer-lasting symptom relief.
Although larger animal studies and clinical research will be needed to determine whether the same mechanism operates in humans, the findings add to growing evidence that chronic itch is not simply a skin condition but a complex neurological process involving communication between the skin, nerves, spinal cord, and brain.
While the research remains at a preclinical stage, identifying the neural mechanisms that help signal when to stop scratching may ultimately support the development of more precise therapies for people living with chronic itch conditions.
